Contract drug manufacturer (CDMO) and branded-generics maker with 9 manufacturing blocks across Baddi, Dehradun, Taloja and Jammu.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 12 | 12 | 12 | 48 | 57 | 57 | 57 | 57 |
| Reserves | 98 | 133 | 197 | 229 | 774 | 902 | 964 | 1.0k |
| Borrowings | 54 | 46 | 199 | 237 | 245 | 338 | 336 | 344 |
| Other Liabilities | 81 | 179 | 167 | 191 | 240 | 271 | 335 | 401 |
| Total Liabilities | 245 | 370 | 575 | 704 | 1.3k | 1.6k | 1.7k | 1.8k |
| AssetsFixed Assets | 73 | 79 | 183 | 183 | 358 | 830 | 847 | 842 |
| CWIP | 0 | 7 | 0 | 22 | 341 | 23 | 7 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 |
| Other Assets | 172 | 283 | 392 | 500 | 617 | 716 | 838 | 938 |
| Total Assets | 245 | 370 | 575 | 704 | 1.3k | 1.6k | 1.7k | 1.8k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 19 | 31 | 42 | 59 | 67 | 146 | 64 | 117 |
| Cash from Investing | -9 | -6 | -20 | -188 | -91 | -499 | -152 | -107 |
| Cash from Financing | -9 | -23 | -19 | 125 | 27 | 361 | 92 | -22 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 11 | 27 | 23 | -21 | -11 | -141 | -108 | 55 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (35.2×) and current (38.6×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 21.8% growth and a 35× exit, ₹950 only delivers your return if you pay ₹1,048. The price is currently baking in 20% growth.
EPS grows 21.8%/yr for 5 years, then fades to 6% over 2, exits at 35×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 21.8% | 29.99 |
| FY28 | 21.8% | 36.52 |
| FY29 | 21.8% | 44.49 |
| FY30 | 21.8% | 54.18 |
| FY31 | 21.8% | 66.00 |
| FY32 | 13.9% ·fade | 75.17 |
| FY33 | 6.0% ·fade | 79.68 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.